Immunologic impact of maraviroc in clinical practice of a university hospital

Maraviroc (MVC) is one of newest antiretrovirals. Several studies have assessed the impact of MVC on CD4 count, although few have analyzed it in clinical practice. We assessed the immunological impact of MVC in clinical practice in a university hospital. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P39 Cite this article as: Paniagua et al.: Immunologic impact of maraviroc in clinical practice of a university hospital. Journal of the International AIDS Society 2010 13(Suppl 4):P39. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113041/